Nucleophosmin Mutations Induce Chemosensitivity in THP-1 Leukemia Cells by Suppressing NF-κB Activity and Regulating Bax/Bcl-2 Expression

Shuaishuai Zhang, Fengxian Qin, Liyuan Yang, Jingrong Xian, Qin Zou, Hongjun Jin, Lu Wang, Ling ZhangJournal of Cancer 2016 · DOI

Abstract

Nucleophosmin (NPM1) is a gene encoding a multifunctional nuclear protein. Mutations in NPM1 occur in approximately one-third of acute myeloid leukemia (AML) cases and are generally associated with a favorable response to induction chemotherapy. However, the mechanisms underlying this chemosensitivity remain poorly understood. This study investigates the role of the NPM1 mutation variant (NPM1mA) in human monocytic leukemia THP-1 cells. We demonstrate that overexpression of NPM1mA sensitizes cells to apoptosis induced by daunorubicin (DNR) and cytarabine (Ara-C) by suppressing NF-κB transcriptional activity and shifting the Bax/Bcl-2 expression ratio toward a pro-apoptotic state. These findings are further supported by clinical data from The Cancer Genome Atlas (TCGA), suggesting a molecular basis for the improved prognosis of NPM1-mutated AML patients.

Introduction

Acute myeloid leukemia (AML) is characterized by significant genetic heterogeneity, which dictates patient prognosis and treatment response. A key genetic marker is the mutation of the Nucleophosmin (NPM1) gene, found in about 30% of AML patients. Clinically, these patients often exhibit a superior response to standard chemotherapy compared to those with wild-type NPM1. Despite its clinical significance, the molecular mechanisms driving this increased sensitivity have been elusive.

A major factor in chemotherapy resistance is the activation of survival pathways, notably the Nuclear Factor-kappa B (NF-κB) pathway. NF-κB acts as a "survival switch," upregulating anti-apoptotic genes in response to cellular stress, such as drug treatment. This study explores whether NPM1 mutations interfere with this survival mechanism to render leukemia cells more vulnerable to treatment.

Materials and Methods

The researchers employed a human monocytic leukemia cell line, THP-1, as an experimental model. These cells were transfected with a vector expressing the common NPM1 mutation variant, NPM1mA, to create a stable mutant line. Control groups included blank (untransfected) cells and cells transfected with an empty vector (pEGFPC1).

To validate the model, the expression of NPM1mA was confirmed at the mRNA level using reverse transcription PCR (RT-PCR) and at the protein level using immunohistochemistry.

Validation of NPM1mA expression in THP-1 cells via RT-PCR (A) and immunohistochemistry (B).

The cells were then subjected to treatment with standard AML chemotherapeutic agents: Daunorubicin (DNR) and Cytarabine (Ara-C). Apoptosis rates were measured via flow cytometry. Transcriptional activity of NF-κB was quantified using luciferase reporter assays. Furthermore, the expression levels of the pro-apoptotic protein Bax and the anti-apoptotic protein Bcl-2 were analyzed using qRT-PCR and Western blotting. To confirm the causal role of NF-κB, a rescue experiment was performed using TNF-α to reactivate the pathway. Finally, the laboratory findings were validated against clinical gene expression data from 165 AML patients in the TCGA dataset.

Results

NPM1mA Enhances Chemotherapy-Induced Apoptosis

Overexpression of the NPM1mA mutation significantly increased the sensitivity of THP-1 cells to chemotherapy. Following DNR treatment, the percentage of apoptotic cells in the NPM1mA-expressing group was approximately 36.5%, compared to roughly 21% in the control groups. Similar results were observed with Ara-C treatment, confirming that the mutation actively promotes cell death in response to these drugs.

Suppression of the NF-κB Survival Pathway

The study found that the presence of the NPM1 mutation blunts the cell's stress response. In control cells, chemotherapy typically activates NF-κB as a survival mechanism. However, in NPM1mA-expressing cells, NF-κB transcriptional activity was reduced by more than half compared to controls upon drug exposure. The rescue experiment demonstrated that when NF-κB activity was restored using TNF-α, the chemosensitizing effect of the NPM1 mutation was attenuated, proving that NF-κB suppression is a central mechanism.

Regulation of the Bax/Bcl-2 Ratio

The mutation was found to shift the balance of the "Bax/Bcl-2 rheostat." Mutant cells showed a significant upregulation of the pro-apoptotic protein Bax and a concurrent downregulation of the anti-apoptotic protein Bcl-2 at both mRNA and protein levels. This shift lowers the threshold for triggering programmed cell death.

Clinical Validation via TCGA

Analysis of the TCGA dataset corroborated these laboratory findings. Patients with NPM1 mutations exhibited significantly higher expression of Bax ($P < 0.0001$) and lower expression of Bcl-2 ($P = 0.0024$) compared to patients with wild-type NPM1. This clinical correlation reinforces the biological relevance of the in vitro results.

Discussion and Conclusion

This research provides a molecular explanation for the favorable prognosis associated with NPM1-mutated AML. By suppressing the NF-κB survival pathway and modulating the Bax/Bcl-2 ratio, the NPM1 mutation prevents leukemia cells from resisting the apoptotic signals induced by chemotherapy.

While these results are compelling, the study has limitations. The functional experiments were conducted in a single cell line (THP-1), and further validation in primary patient samples or animal models is necessary. Additionally, the precise biochemical interaction between the mutant NPM1 protein and the NF-κB complex remains to be elucidated. Future research should also explore whether other signaling pathways, such as p53 or AKT, contribute to this chemosensitivity.

In conclusion, the study identifies the NF-κB/Bax/Bcl-2 axis as a critical mediator of chemosensitivity in NPM1-mutated AML, offering potential targets for future therapeutic strategies aimed at overcoming drug resistance in other leukemia subtypes.

Summary updated

Abstract

<i>Nucleophosmin</i> (<i>NPM1</i>) - a gene that encodes for a nuclear protein with multiple functions. Mutations in <i>NPM1</i> are seen in approximately one-third of acute myeloid leukemia (AML) and are generally associated with good response to induction chemotherapy. However, the mechanisms underlying this chemosensitivity are still unknown. Recent studies have established that nuclear factor-κB (NF-κB) activation is a key response of leukemia cell to chemotherapy. In this study, we transfected human monocytic leukemia THP-1 cells with the vector expressing NPM1 mutation variant (NPM1mA), and confirmed overexpression of NPM1mA at mRNA and protein levels by reverse transcription PCR (RT-PCR) and immunohistochemistry, respectively. The effects of NPM1 mutations on chemotherapeutical agents induced apoptosis, NF-κB activity and gene expression were examined using flow cytometry, luciferase reporter assays, quantitative real time PCR (qRT-PCR) and Western blot. We found that overexpression of NPM1mA in THP-1 cells sensitized these cells to apoptosis induced by chemotherapeutical agents such as daunorubicin (DNR) and cytarabine (Ara-C). Moreover, we demonstrated that expression of NPM1 mA reduced the NF-κB transcription activity of THP-1 cells upon drug treatment. In addition, restoration of NF-κB activity via TNF-α stimulation could attenuate the effect of NPM1mA overexpression on DNR-and Ara-C-induced apoptosis. Interestingly, expression of NPM1mA could upregulate Bax and downregulate Bcl-2 at mRNA and protein levels in THP-1 cells when treated with DNR or Ara-C. We also demonstrated that restoration of NF-κB activity via TNF-α pre-treatment reversed the effect of NPM1mA on the Bax/Bcl-2 expression. Furthermore, evaluation of gene expression data from The Cancer Genome Atlas (TCGA) dataset revealed that NPM1-mutated patients showed a higher expression of Bax and a lower expression of Bcl-2. These results suggest that the NPM1 gene mutations could confer increased sensitivity to chemotherapeutic agents, at least in part, by suppressing NF-κB activity and regulating Bax/Bcl-2 expression.
BibTeX
@article{zhang2016nucleophosmin,
  author = {Shuaishuai Zhang and Fengxian Qin and Liyuan Yang and Jingrong Xian and Qin Zou and Hongjun Jin and Lu Wang and Ling Zhang},
  title = {{Nucleophosmin Mutations Induce Chemosensitivity in THP-1 Leukemia Cells by Suppressing NF-κB Activity and Regulating Bax/Bcl-2 Expression}},
  journal = {Journal of Cancer},
  year = {2016},
  doi = {10.7150/jca.16010},
}
Figure